A quantitative systems pharmacology workflow toward optimal design and biomarker stratification of atopic dermatitis clinical trials

Atopic dermatitis (AD) is a chronic inflammatory condition of the skin characterized by recurrent eczematous lesions and intense itch that can profoundly impair quality of life.1-6 The pathophysiology of AD is complex and involves local and systemic immune dysregulation, genetic susceptibility, environmental factors, and microbiome effects.7,8 AD is a heterogeneous disease that encompasses a variety of endotypes and phenotypes (see the work cited in Facheris et  al9). The road to novel AD therapeutics10 is tortuous due to a combination of 2 factors:
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research